Li LianQiang, Zhang Xiao
Department of Urology, General Hospital of Northern Theater Command, Shenyang, China.
Emergency Medical Center, The First Hospital of Shanxi Medical University, Taiyuan, China.
Cancer Biol Ther. 2025 Dec;26(1):2545653. doi: 10.1080/15384047.2025.2545653. Epub 2025 Aug 22.
To explore the expression of miR-135a-3p in prostate cancer,analyze its effects on tumor development and the involved mechanisms. A total of 125 specimens of cancer tissues and corresponding adjacent normal tissues from prostate cancer patients were collected. Real - Time quantitative PCR was employed to quantify the expression levels of miR-135a-3p in prostate cancer tissues and cell lines. Kaplan-Meier survival curve analysis and Cox regression were performed to evaluate the prognostic significance of miR-135a-3p in prostate cancer. The CCK-8 assay was used to detect cell proliferation. A dual-luciferase reporter assay was employed to validate the targeting interaction between miR-135a-3p and Toll-like receptor 4 (TLR4). miR-135a-3p is lowly expressed in prostate cancer tissues and cells, and its low expression is associated with poor prognosis of patients. The low expression state of miR-135a-3p showed a significant correlation with TNM stage, clinical stage, Gleason score, and lymph node metastasis. In addition, miR-135a-3p inhibits the proliferation of prostate cancer cells and cancer progression by negatively regulating the expression of TLR4. miR-135a-3p is downregulated in prostate cancer and is associated with poor prognosis of patients. It exerts an inhibitory effect on the progression of prostate cancer by targeting TLR4.
为探究miR-135a-3p在前列腺癌中的表达情况,分析其对肿瘤发展的影响及相关机制。共收集了125例前列腺癌患者的癌组织标本及相应的癌旁正常组织标本。采用实时定量PCR技术检测前列腺癌组织及细胞系中miR-135a-3p的表达水平。进行Kaplan-Meier生存曲线分析和Cox回归分析,以评估miR-135a-3p在前列腺癌中的预后意义。采用CCK-8法检测细胞增殖情况。运用双荧光素酶报告基因检测法验证miR-135a-3p与Toll样受体4(TLR4)之间的靶向相互作用。miR-135a-3p在前列腺癌组织和细胞中低表达,其低表达与患者预后不良相关。miR-135a-3p的低表达状态与TNM分期、临床分期、Gleason评分及淋巴结转移显著相关。此外,miR-135a-3p通过负调控TLR4的表达抑制前列腺癌细胞的增殖和肿瘤进展。miR-135a-3p在前列腺癌中表达下调,与患者预后不良相关。它通过靶向TLR4对前列腺癌的进展发挥抑制作用。
Cancer Biol Ther. 2025-12
Zhonghua Zhong Liu Za Zhi. 2025-7-23
J Obstet Gynaecol. 2025-12
Medicine (Baltimore). 2020-5-29
J Cancer Res Clin Oncol. 2017-2
Sichuan Da Xue Xue Bao Yi Xue Ban. 2025-3-20
Zhonghua Bing Li Xue Za Zhi. 2025-7-8
Cancers (Basel). 2025-3-17
BMC Urol. 2024-11-6
Cancer Rep (Hoboken). 2024-10
Pathol Res Pract. 2023-8
Front Oncol. 2023-2-28
Comput Biol Med. 2023-1
Biomed Pharmacother. 2023-1